Liquidia
Manufacturing · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
419 Davis Dr Ste 100, Morrisville, North...Phone Number
(919) 328-4400Website
www.liquidia.comRevenue
$288.1 MillionStock Symbol
LQDAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Liquidia
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC.Explore more
Liquidia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Liquidia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Liquidia launches new products
Check if Liquidia has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Liquidia
Click to see if Liquidia had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Liquidia recently announced quarterly report
Website visits: Recent activity has been detected on your website
Liquidia, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Liquidia is spiking on competitors!
Funding: Get notified immidiatlly once Liquidia has new funding data
Recommended Actions
Reach out to Masked Content who joined Liquidia as Masked Content
Find 3 more new buyers
Compare Similar Companies to Liquidia
Compare insights from companies similar to Liquidia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$12.2M
11-50
Private
<$5M
1981
JS
Jonathan Schwartz(Performing At Director, Operations & Vice President, Level)
Company Profile Activity
Activity Insights
Liquidia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Liquidia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Liquidia.
Liquidia financials insights
Gather financial insights about Liquidia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Series A
$6M
2007
Series B
$16M
2010
Series C
$25M
2018
Series D
$25.5M
2021
Debt
$20.5M
2022
Debt
$40M
2025
Debt
$100M
Liquidia Tech Stack
A closer look at the technologies used by Liquidia
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
Person-Based
Earnings, Product Development, Finance
Person-Based
Research & Development, Pharmaceuticals
Person-Based
Pharmaceuticals
Liquidia News & Media
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Liquidia (Nasdaq: LQDA): FDA grants Fast Track designation to YUTREPIA for systemic sclerosis-associated Raynaud's phenomenon; Phase 2a study in Q4 2026Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company’s business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET.Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Liquidia
Sign Up For FreeTo access detailed company insights
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of... Read More
